Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.34 |
| ▸ | PDE2A | O00408 | 5/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820308 | 0.84 | CYP19A1 (0.35) | CYP19A1LRRK2CCR1CCR8 | |
| SCHEMBL17108199 | 0.82 | CCR1 (0.53) | CYP19A1LRRK2PDE2ACCR1CCR8 | |
| SCHEMBL17108200 | 0.81 | BTK (0.42) | — | |
| SCHEMBL31173176 | 0.78 | BRD4 (0.37) | CCR1CCR8GABRA1GABRG2GABRB3 | |
| SCHEMBL3510772 | 0.78 | BRD4 (0.37) | CCR1CCR8GABRA1GABRG2GABRB3 | |
| SCHEMBL3508024 | 0.77 | JAK2 (0.36) | CYP19A1PDE2A | |
| SCHEMBL17055767 | 0.74 | CCNK (0.42) | CYP19A1 | |
| SCHEMBL17108202 | 0.73 | FLT3 (0.54) | CYP19A1CCR1CCR8 | |
| SCHEMBL26529057 | 0.73 | KDM5B (0.44) | — | |
| SCHEMBL19449442 | 0.72 | LMNA (0.41) | CYP19A1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | CYP19A1 4299/4885LRRK2 1908/4885PDE2A 1001/4885 |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | CYP19A1 4299/4885LRRK2 1908/4885PDE2A 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.